These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 22237835)

  • 1. Adjuvant PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) or gemcitabine followed by chemoradiation in pancreatic cancer: a randomized phase II trial.
    Reni M; Balzano G; Aprile G; Cereda S; Passoni P; Zerbi A; Tronconi MC; Milandri C; Saletti P; Rognone A; Fugazza C; Magli A; Di Muzio N; Di Carlo V; Villa E
    Ann Surg Oncol; 2012 Jul; 19(7):2256-63. PubMed ID: 22237835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma.
    Reni M; Cereda S; Bonetto E; Viganò MG; Passoni P; Zerbi A; Balzano G; Nicoletti R; Staudacher C; Di Carlo V
    Cancer Chemother Pharmacol; 2007 Feb; 59(3):361-7. PubMed ID: 16807732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial.
    Reni M; Cordio S; Milandri C; Passoni P; Bonetto E; Oliani C; Luppi G; Nicoletti R; Galli L; Bordonaro R; Passardi A; Zerbi A; Balzano G; Aldrighetti L; Staudacher C; Villa E; Di Carlo V
    Lancet Oncol; 2005 Jun; 6(6):369-76. PubMed ID: 15925814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II Trial of Postoperative Adjuvant Gemcitabine and Cisplatin Chemotherapy Followed by Chemoradiotherapy with Gemcitabine in Patients with Resected Pancreatic Cancer.
    Lee KH; Chie EK; Im SA; Kim JH; Kwon J; Han SW; Oh DY; Jang JY; Kim JS; Kim TY; Bang YJ; Kim SW; Ha SW
    Cancer Res Treat; 2021 Oct; 53(4):1096-1103. PubMed ID: 33421976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) regimen as second-line therapy in patients with progressive or recurrent pancreatic cancer after gemcitabine-containing chemotherapy.
    Reni M; Cereda S; Mazza E; Passoni P; Nicoletti R; Balzano G; Zerbi A; Arcidiacono PG; Staudacher C; Di Carlo V
    Am J Clin Oncol; 2008 Apr; 31(2):145-50. PubMed ID: 18391598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen).
    Reni M; Cereda S; Rognone A; Belli C; Ghidini M; Longoni S; Fugazza C; Rezzonico S; Passoni P; Slim N; Balzano G; Nicoletti R; Cappio S; Doglioni C; Villa E
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):115-23. PubMed ID: 21626049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Final results of a prospective trial of a PEFG (Cisplatin, Epirubicin, 5-Fluorouracil, Gemcitabine) regimen followed by radiotherapy after curative surgery for pancreatic adenocarcinoma.
    Reni M; Passoni P; Bonetto E; Balzano G; Panucci MG; Zerbi A; Ronzoni M; Staudacher C; Villa E; Di Carlo V
    Oncology; 2005; 68(2-3):239-45. PubMed ID: 16015040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant interferon-based chemoradiation followed by gemcitabine for resected pancreatic adenocarcinoma: a single-institution phase II study.
    Linehan DC; Tan MC; Strasberg SM; Drebin JA; Hawkins WG; Picus J; Myerson RJ; Malyapa RS; Hull M; Trinkaus K; Tan BR
    Ann Surg; 2008 Aug; 248(2):145-51. PubMed ID: 18650621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Definitive results of a phase II trial of cisplatin, epirubicin, continuous-infusion fluorouracil, and gemcitabine in stage IV pancreatic adenocarcinoma.
    Reni M; Passoni P; Panucci MG; Nicoletti R; Galli L; Balzano G; Zerbi A; Di Carlo V; Villa E
    J Clin Oncol; 2001 May; 19(10):2679-86. PubMed ID: 11352960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma: a dose-finding study.
    Reni M; Cereda S; Bonetto E; Viganò MG; Passoni P; Zerbi A; Balzano G; Nicoletti R; Staudacher C; Di Carlo V
    Cancer Invest; 2007; 25(7):594-8. PubMed ID: 17852117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cisplatin, epirubicin, 5-fluorouracil, gemcitabine (PEFG) regimen in advanced biliary tract adenocarcinoma.
    Cereda S; Passoni P; Reni M; Viganò MG; Aldrighetti L; Nicoletti R; Villa E
    Cancer; 2010 May; 116(9):2208-14. PubMed ID: 20187098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) for patients with advanced pancreatic cancer: the ghost regimen.
    Reni M; Cereda S; Galli L
    Cancer Lett; 2007 Oct; 256(1):25-8. PubMed ID: 17561341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interferon-based chemoradiation followed by gemcitabine for resected pancreatic adenocarcinoma: long-term follow-up.
    Ohman KA; Liu J; Linehan DC; Tan MC; Tan BR; Fields RC; Strasberg SM; Hawkins WG
    HPB (Oxford); 2017 May; 19(5):449-457. PubMed ID: 28162923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial.
    Regine WF; Winter KA; Abrams R; Safran H; Hoffman JP; Konski A; Benson AB; Macdonald JS; Rich TA; Willett CG
    Ann Surg Oncol; 2011 May; 18(5):1319-26. PubMed ID: 21499862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival and quality of life of patients with resected pancreatic adenocarcinoma treated with adjuvant interferon-based chemoradiation: a phase II trial.
    Katz MH; Wolff R; Crane CH; Varadhachary G; Javle M; Lin E; Evans DB; Lee JE; Fleming JB; Pisters PW
    Ann Surg Oncol; 2011 Dec; 18(13):3615-22. PubMed ID: 21701927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance).
    Fuchs CS; Niedzwiecki D; Mamon HJ; Tepper JE; Ye X; Swanson RS; Enzinger PC; Haller DG; Dragovich T; Alberts SR; Bjarnason GA; Willett CG; Gunderson LL; Goldberg RM; Venook AP; Ilson D; O'Reilly E; Ciombor K; Berg DJ; Meyerhardt J; Mayer RJ
    J Clin Oncol; 2017 Nov; 35(32):3671-3677. PubMed ID: 28976791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patterns of Failure for Lymph Node-Positive Resected Pancreatic Adenocarcinoma After Adjuvant Radiotherapy or Gemcitabine-based Chemotherapy Alone.
    McDonald AM; Dulaney CR; López-Araujo J; Posey JA; Keene KS; Christein JD; Heslin MJ; Wood TE; Jacob R
    J Gastrointest Cancer; 2015 Jun; 46(2):149-55. PubMed ID: 25782589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of gemcitabine, epirubicin and granulocyte colony-stimulating factor in patients with advanced pancreatic adenocarcinoma.
    Scheithauer W; Kornek GV; Raderer M; Hejna M; Valencak J; Miholic J; Kovats E; Lang F; Funovics J; Bareck E; Depisch D
    Br J Cancer; 1999 Aug; 80(11):1797-802. PubMed ID: 10468299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer: results of the first prospective randomized phase II trial.
    Golcher H; Brunner TB; Witzigmann H; Marti L; Bechstein WO; Bruns C; Jungnickel H; Schreiber S; Grabenbauer GG; Meyer T; Merkel S; Fietkau R; Hohenberger W
    Strahlenther Onkol; 2015 Jan; 191(1):7-16. PubMed ID: 25252602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemoradiotherapy with concurrent gemcitabine and cisplatin with or without sequential chemotherapy with gemcitabine/cisplatin vs chemoradiotherapy with concurrent 5-fluorouracil in patients with locally advanced pancreatic cancer--a multi-centre randomised phase II study.
    Wilkowski R; Boeck S; Ostermaier S; Sauer R; Herbst M; Fietkau R; Flentje M; Miethe S; Boettcher HD; Scholten T; Bruns CJ; Rau HG; Hinke A; Heinemann V
    Br J Cancer; 2009 Dec; 101(11):1853-9. PubMed ID: 19904268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.